Goldman Charge Curbs Enthusiasm for Market Risk
Larger Cap Healthcare Stocks Holding Up Well The SEC charges against Goldman Sachs have taken the MO out of the market with speculative issues down considerably. As of midday trading the Dow is down 1.2%. NASDAQ down 1.5% and the S&P down 1.6%.Stocks are off their lows. Large Cap healthcare...
Rayno Life Science Portfolio 2010: Biopharmaceuticals
Exelixis (EXEL) added as speculative buy at $3.30 on 9/2/10 Update: Portfolio rebalancing below but we are still in a bearish mode with small cap biotech. The brief rally spurred by a potential buyout rumor by Sanofi last Friday has evaporated with Biogen,Celgene Genzyme and Gilead all down....
Rayno Life Science Portfolio : Diagnostics and Tools, Quidel and Celera
Quidel (QDEL) was up 7.9% yesterday to $12.13 on volume of 375k shares. This stock is now under review and is a value buy in the $12 range. Quidel bought Diagnostic Hybrids for for $131M in Q1 bringing debt to $83M. Wedbush upgraded the stock on May 27. Celera(CRA) is being added as a buy at $7...
Immucor(BLUD) Profits Up but Stock Down 8 %
Immucor (BLUD) a global leader in providing instrument-reagent systems to the blood transfusion industry delivered more than expected financial results for the 3rd Quarter of fiscal 2010 ended February 28. Revenue of $80.5M was up 7% from prior year quarter. Gross margin was 69.2% compared to...
Gene Patent Ruling stalls Biotech Rally-Myriad (MYGN) down 4.9%
US Judge invalidates cancer gene patents Intellectual Property (IP) is the raw material for the creation of biotech companies. Without an invention covered by a robust patent portfolio, venture funding can be very difficult. Since the beginning of the "genomic age" in the late nineties the...